Pulmonary Hypertension Impact Factor|omicsgroup|journal Of Vascular Medicaine And Surgery

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Pulmonary Hypertension Impact Factor

It is characterized by rising in blood pressure in the pulmonary artery and pulmonary vein which leads to shortness of breath, dizziness, fainting, leg swelling etc. it can be diagnosed by pulmonary function tests, blood tests except HIV, ECG, arterial blood gas measurements, X-rays of the chest, CT scanning. Pulmonary hypertension can be treated by diuretics, beta blockers, ACE inhibitors etc.The impact factor of journal provides quantitative assessment tool for grading, evaluating, sorting and comparing journals of similar kind. It reflects the average number of citations to recent articles published in science and social science journals in a particular year or period, and is frequently used as a proxy for the relative importance of a journal within its field. It is first devised by Eugene Garfield, the founder of the Institute for Scientific Information.The impact factor of a journal is evaluated by dividing the number of current year citations to the source items published in that journal during the previous two years.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on March, 2021